ALGS
Aligos reports Q3 '26 progress, cash falls to $31.1M
Aligos Therapeutics reported cash of $31.1 million as of September 30, down from $77.8 million at year-end 2025. R&D decreased due to lower Phase 2 trial costs as the company initiates a Phase 1 study in China for its candidate ALG-170675.
Earnings|Guidance|M&A|Buyback|Dividend|Leadership|Restructuring|Regulatory|Legal|Cyber|Offering|Bankruptcy|Other
Nov 6, 2026
sentiment -0.40
SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.